SCHEMBL3170368

SCHEMBL3170368

COc1cc(Nc2ncc(C(N)=O)c(Nc3ccc(S(C)(=O)=O)cc3)n2)cc(OC)c1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 3/20 0.66
MAPK9 P45984 2/20 0.66
SYK P43405 15/20 0.62
PTK2 Q05397 2/20 0.56
CDC7 O00311 1/20 0.56
PLK4 O00444 1/20 0.56
CHEK1 O14757 1/20 0.56
DCLK1 O15075 1/20 0.56
CHUK O15111 1/20 0.56
PDPK1 O15530 1/20 0.56
DAPK3 O43293 1/20 0.56
DYRK3 O43781 1/20 0.56
JAK2 O60674 1/20 0.56
ROCK2 O75116 1/20 0.56
PRKD3 O94806 1/20 0.56
MAP4K4 O95819 1/20 0.56
PAK4 O96013 1/20 0.56
CHEK2 O96017 1/20 0.56
ABL1 P00519 1/20 0.56
NTRK1 P04629 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3167410 0.90 MAPK8 (0.66) MAPK8MAPK9SYKPTK2CDC7
SCHEMBL3174674 0.88 MAPK8 (0.70) MAPK8MAPK9SYKPTK2CDC7
SCHEMBL3166777 0.88 MAPK8 (0.70) MAPK8MAPK9SYKPTK2CDC7
SCHEMBL14657660 0.87 MAPK8 (0.82) MAPK8MAPK9SYKPTK2CDC7
SCHEMBL3160584 0.84 MAPK8 (0.65) MAPK8MAPK9SYKPTK2CDC7
SCHEMBL10244483 0.83 SYK (0.71) MAPK8MAPK9SYKPTK2CDK1
SCHEMBL3171302 0.81 ITK (0.70) MAPK8MAPK9SYKPTK2CDC7
SCHEMBL3177662 0.81 MAPK8 (0.70) MAPK8MAPK9SYKAURKB
SCHEMBL762023 0.81 SYK (0.74) MAPK8MAPK9SYKJAK2JAK3
SCHEMBL3174125 0.80 MAPK8 (0.68) MAPK8MAPK9SYKPTK2CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100010025-A1 Pyrimidine Derivatives NORVARTIS AG 2010-01-14 US disclosed
US-20100010025-A1 Pyrimidine Derivatives NORVARTIS AG 2010-01-14 US disclosed
US-20100010025-A1 Pyrimidine Derivatives NORVARTIS AG 2010-01-14 US disclosed
WO-2008009458-A1 2, 4 -DI (ARYLAMINIO) -PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS AS JAK KINASES INHIBITORS NOVARTIS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010025-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS MAPK8 2532/4885MAPK9 2772/4885SYK 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.